TABLE OF CONTENTS
1 INTRODUCTION 118
1.1 OBJECTIVES OF THE STUDY 118
1.2 MARKET DEFINITION 118
1.3 OVERVIEW OF THE GLOBAL UTERINE CANCER DIAGNOSTIC MARKET 118
1.4 CURRENCY AND PRICING 120
1.5 LIMITATIONS 120
1.6 MARKETS COVERED 120
2 MARKET SEGMENTATION 128
2.1 MARKETS COVERED 128
2.2 GEOGRAPHICAL SCOPE 129
2.3 YEARS CONSIDERED FOR THE STUDY 130
2.4 DBMR TRIPOD DATA VALIDATION MODEL 131
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 134
2.6 MULTIVARIATE MODELLING 135
2.7 MARKET APPLICATION COVERAGE GRID 136
2.8 INSTRUMENT BASED LIFELINE CURVE 137
2.9 DBMR MARKET POSITION GRID 138
2.10 VENDOR SHARE ANALYSIS 140
2.11 SECONDARY SOURCES 141
2.12 ASSUMPTIONS 141
3 EXECUTIVE SUMMARY 142
4 PREMIUM INSIGHTS 145
4.1 PESTEL ANALYSIS 148
4.2 PORTERS FIVE FORCES 149
4.3 PATENT ANALYSIS OF GLOBAL UTERINE CANCER DIAGNOSTICS MARKET 150
4.4 REIMBURSEMENT SCENARIO 151
4.5 INDUSTRY INSIGHTS: 152
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 152
4.7 PRICING STRATEGIES 152
4.8 CONCLUSION 153
4.9 PREVALENCE, INCIDENCE, AND MORTALITY RATE OF UTERINE CANCER 154
4.10 COST OF UTERINE CANCER PROCEDURE 156
5 REGULATORY FRAMEWORK 157
6 MARKET OVERVIEW 159
6.1 DRIVERS 161
6.1.1 TECHNOLOGICAL ADVANCEMENTS IN UTERINE CANCER DIAGNOSTICS 161
6.1.2 RISING DEMAND FOR MINIMALLY INVASIVE ADVANCED SCREENING TECHNIQUES 161
6.1.3 RISING AWARENESS TOWARDS UTERINE CANCER 162
6.1.4 RISING IMPORTANCE OF WOMEN'S HEALTH 162
6.2 RESTRAINTS 163
6.2.1 HIGH RISK COMPLICATIONS DURING DIAGNOSTIC TESTS 163
6.2.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF UTERINE CANCER 163
6.3 OPPORTUNITIES 164
6.3.1 INCREASING PREVALENCE OF UTERINE CANCER 164
6.3.2 RISE IN ADOPTION OF SEDENTARY LIFESTYLE 164
6.3.3 GROWTH IN MENSTRUAL COMPLICATIONS 165
6.4 CHALLENGES 165
6.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 165
6.4.2 HIGH COST OF IMAGING SYSTEMS 166
7 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE 167
7.1 OVERVIEW 168
7.2 INSTRUMENT-BASED 171
7.2.1 ULTRASOUND SCANNING 172
7.2.1.1 SYSTEMS 172
7.2.1.2 ABDOMINAL ULTRASOUND SCANNING 173
7.2.1.3 TRANSVAGINAL ULTRASOUND SCANNING 173
7.2.1.4 ACCESSORIES 173
7.2.2 IMAGING DEVICES 173
7.2.2.1 CT/PET (POSITRON EMISSION TOMOGRAPHY) SCAN 174
7.2.2.2 MAGNETIC RESONANCE IMAGING (MRI) 174
7.2.2.3 COMPUTED TOMOGRAPHY (CT) SCAN 174
7.2.2.4 OTHERS 174
7.2.3 TESTS 175
7.2.3.1 BLOOD TESTS 175
7.2.3.1.1 COMPLETE BLOOD COUNT 175
7.2.3.1.2 CA125 MARKER BLOOD TEST 175
7.2.3.2 URINE TESTS 176
7.2.3.3 OTHER TESTS 176
7.2.4 OTHERS 176
7.3 PROCEDURE BASED 176
7.3.1 ENDOMETRIAL BIOPSY 177
7.3.2 HYSTEROSCOPY 177
7.3.3 DILATION & CURETTAGE 177
7.3.4 CYSTOSCOPY 177
7.3.5 PROCTOSCOPY 178
7.3.6 OTHERS 178
8 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE 179
8.1 OVERVIEW 180
8.2 ENDOMETRIAL CANCER 183
8.2.1 SEROUS ADENOCARCINOMA 184
8.2.1.1 INSTRUMENT-BASED 184
8.2.1.1.1 ULTRASOUND SCANNING 185
8.2.1.1.2 IMAGING DEVICES 185
8.2.1.1.3 TESTS 185
8.2.1.1.4 OTHERS 185
8.2.1.2 PROCEDURE-BASED 186
8.2.1.2.1 ENDOMETRIAL BIOPSY 186
8.2.1.2.2 HYSTEROSCOPY 186
8.2.1.2.3 DILATION & CURETTAGE 186
8.2.1.2.4 CYSTOSCOPY 186
8.2.1.2.5 PROCTOSCOPY 186
8.2.1.2.6 OTHERS 187
8.2.2 ADENOSQUAMOUS CARCINOMA 187
8.2.2.1 INSTRUMENT-BASED 187
8.2.2.1.1 ULTRASOUND SCANNING 187
8.2.2.1.2 IMAGING DEVICES 188
8.2.2.1.3 TESTS 188
8.2.2.1.4 OTHERS 188
8.2.2.2 PROCEDURE-BASED 188
8.2.2.2.1 ENDOMETRIAL BIOPSY 188
8.2.2.2.2 HYSTEROSCOPY 188
8.2.2.2.3 DILATION & CURETTAGE 189
8.2.2.2.4 CYSTOSCOPY 189
8.2.2.2.5 PROCTOSCOPY 189
8.2.2.2.6 OTHERS 189
8.2.3 UTERINE CARCINOSARCOMA 189
8.2.3.1 INSTRUMENT-BASED 189
8.2.3.1.1 ULTRASOUND SCANNING 190
8.2.3.1.2 IMAGING DEVICES 190
8.2.3.1.3 TESTS 190
8.2.3.1.4 OTHERS 190
8.2.3.2 PROCEDURE-BASED 191
8.2.3.2.1 ENDOMETRIAL BIOPSY 191
8.2.3.2.2 HYSTEROSCOPY 191
8.2.3.2.3 DILATION & CURETTAGE 191
8.2.3.2.4 CYSTOSCOPY 191
8.2.3.2.5 PROCTOSCOPY 191
8.2.3.2.6 OTHERS 192
8.2.4 PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM 192
8.2.4.1 INSTRUMENT-BASED 192
8.2.4.1.1 ULTRASOUND SCANNING 192
8.2.4.1.2 IMAGING DEVICES 193
8.2.4.1.3 TESTS 193
8.2.4.1.4 OTHERS 193
8.2.4.2 PROCEDURE-BASED 193
8.2.4.2.1 ENDOMETRIAL BIOPSY 193
8.2.4.2.2 HYSTEROSCOPY 193
8.2.4.2.3 DILATION & CURETTAGE 194
8.2.4.2.4 CYSTOSCOPY 194
8.2.4.2.5 PROCTOSCOPY 194
8.2.4.2.6 OTHERS 194
8.3 UTERINE SARCOMA 194
8.3.1 LEIOMYOSARCOMA 195
8.3.1.1 INSTRUMENT-BASED 195
8.3.1.1.1 ULTRASOUND SCANNING 196
8.3.1.1.2 IMAGING DEVICES 196
8.3.1.1.3 TESTS 196
8.3.1.1.4 OTHERS 196
8.3.1.2 PROCEDURE-BASED 197
8.3.1.2.1 ENDOMETRIAL BIOPSY 197
8.3.1.2.2 HYSTEROSCOPY 197
8.3.1.2.3 DILATION & CURETTAGE 197
8.3.1.2.4 CYSTOSCOPY 197
8.3.1.2.5 PROCTOSCOPY 197
8.3.1.2.6 OTHERS 198
8.3.2 ENDOMETRIAL STROMAL SARCOMA 198
8.3.2.1 INSTRUMENT-BASED 198
8.3.2.1.1 ULTRASOUND SCANNING 198
8.3.2.1.2 IMAGING DEVICES 199
8.3.2.1.3 TESTS 199
8.3.2.1.4 OTHERS 199
8.3.2.2 PROCEDURE-BASED 199
8.3.2.2.1 ENDOMETRIAL BIOPSY 199
8.3.2.2.2 HYSTEROSCOPY 199
8.3.2.2.3 DILATION & CURETTAGE 200
8.3.2.2.4 CYSTOSCOPY 200
8.3.2.2.5 PROCTOSCOPY 200
8.3.2.2.6 OTHERS 200
8.3.3 UNDIFFERENTIATED SARCOMA 200
8.3.3.1 INSTRUMENT-BASED 201
8.3.3.1.1 ULTRASOUND SCANNING 201
8.3.3.1.2 IMAGING DEVICES 201
8.3.3.1.3 TESTS 201
8.3.3.1.4 OTHERS 201
8.3.3.2 PROCEDURE-BASED 202
8.3.3.2.1 ENDOMETRIAL BIOPSY 202
8.3.3.2.2 HYSTEROSCOPY 202
8.3.3.2.3 DILATION & CURETTAGE 202
8.3.3.2.4 CYSTOSCOPY 202
8.3.3.2.5 PROCTOSCOPY 203
8.3.3.2.6 OTHERS 203
9 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP 204
9.1 OVERVIEW 205
9.2 >60 YEARS 208
9.3 51-60 YEARS 209
9.4 41-50 YEARS 210
9.5 31-40 YEARS 211
9.6 <30 YEARS 212
10 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY END USER 213
10.1 OVERVIEW 214
10.2 HOSPITALS 217
10.3 DIAGNOSTIC CENTERS 218
10.4 CANCER RESEARCH CENTERS 219
10.5 AMBULATORY SURGICAL CENTERS 220
10.6 SPECIALIZED CLINICS 221
10.7 OTHERS 222
11 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 223
11.1 OVERVIEW 224
11.2 DIRECT TENDER 227
11.3 THIRD PARTY DISTRIBUTORS 228
11.4 OTHERS 229
12 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY REGION 230
12.1 OVERVIEW 231
12.2 NORTH AMERICA 236
12.2.1 U.S. 252
12.2.2 CANADA 263
12.2.3 MEXICO 274
12.3 EUROPE 287
12.3.1 GERMANY 303
12.3.2 FRANCE 314
12.3.3 UNITED KINGDOM 326
12.3.4 ITALY 339
12.3.5 SPAIN 351
12.3.6 RUSSIA 362
12.3.7 NETHERLANDS 375
12.3.8 POLAND 388
12.3.9 SWITZERLAND 401
12.3.10 BELGIUM 414
12.3.11 SWEDEN 427
12.3.12 NORWAY 440
12.3.13 DENMARK 453
12.3.14 FINLAND 466
12.3.15 TURKEY 479
12.3.16 REST OF EUROPE 492
12.4 ASIA-PACIFIC 493
12.4.1 CHINA 510
12.4.2 JAPAN 523
12.4.3 INDIA 536
12.4.4 AUSTRALIA 549
12.4.5 TAIWAN 562
12.4.6 NEW ZEALAND 575
12.4.7 SOUTH KOREA 588
12.4.8 SINGAPORE 601
12.4.9 INDONESIA 614
12.4.10 PHILIPPINES 627
12.4.11 VIETNAM 640
12.4.12 THAILAND 653
12.4.13 MALAYSIA 665
12.4.14 REST OF ASIA PACIFIC 678
12.5 SOUTH AMERICA 679
12.5.1 BRAZIL 696
12.5.2 ARGENTINA 709
12.5.3 REST OF SOUTH AMERICA 721
12.6 MIDDLE EAST AND AFRICA 722
12.6.1 SOUTH AFRICA 739
12.6.2 SAUDI ARABIA 752
12.6.3 BAHRAIN 765
12.6.4 UAE 778
12.6.5 EGYPT 790
12.6.6 ISRAEL 803
12.6.7 KUWAIT 816
12.6.8 OMAN 829
12.6.9 QATAR 842
12.6.10 REST OF MIDDLE EAST AND AFRICA 855
13 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 856
13.1 COMPANY SHARE ANALYSIS: GLOBAL 856
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 857
13.3 COMPANY SHARE ANALYSIS: EUROPE 858
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 859
14 SWOT ANALYSIS 860

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.